Laurus Labs pumps $11.3M into KRKA Pharma joint venture
What's the deal? Laurus Labs has invested US$14.6M (roughly $11.3 million) in KRKA Pharma, its joint venture with Slovenia-based KRKA d.d., Novo mesto. The Indian drugmaker bought 107,800,000 equity shares at a face value of US$0.14 each through a rights issue, it disclosed on October 14, 2026.
Why now? The move continues a plan Laurus Labs flagged on April 30, 2026. It brings the company's total holding in KRKA Pharma to 262,150,000 equity shares, while keeping its stake unchanged at 49%.
What's the endgame? KRKA Pharma ties together Indian manufacturer Laurus Labs and Slovenia's KRKA d.d. The fresh capital is meant to strengthen the venture's operations and market position, Laurus Labs said.
The company disclosed the investment under Regulation 30 of India's SEBI listing rules, which require listed firms to share material information promptly.
The signal: For Laurus Labs, topping up a cross-border joint venture rather than acquiring outright reflects a steady strategy to expand through partnerships while holding a minority stake.
Read more: businessupturn.com
Image credit: Generated with Gemini
